Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT’s US deals and activism correspondent Oliver Barnes walks through the tussle that’s involved lawsuits, public barbs and political drama. Clips from CNBC, Pfizer, Yahoo Finance - - - - - - - - - - - - - - - - - - - - - - - - - - For further reading and listening: Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk Pfizer shows hardball mettle needed to win in 2025 M&A There is only one winner in the Pfizer Novo Nordisk showdown Ozempic’s unconventional origins - - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here . - - - - - - - - - - - - - - - - - - - - - - - - - - Follow Oliver Barnes on X ( @mroliverbarnes ), or on Bluesky ( @mroliverbarnes.bsky.social ) Michela Tindera is on X ( @mtindera07 ) and Bluesky ( @mtindera.ft.com ), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.
